MX2021003204A - Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo. - Google Patents

Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo.

Info

Publication number
MX2021003204A
MX2021003204A MX2021003204A MX2021003204A MX2021003204A MX 2021003204 A MX2021003204 A MX 2021003204A MX 2021003204 A MX2021003204 A MX 2021003204A MX 2021003204 A MX2021003204 A MX 2021003204A MX 2021003204 A MX2021003204 A MX 2021003204A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
oxadiazole
composition containing
compound
same
Prior art date
Application number
MX2021003204A
Other languages
English (en)
Inventor
Ju Young Lee
Min Soo Han
Young Soon Kang
Yu Jin Shin
Eun Ju Choi
Choon Ho Ryu
Yeo Jin Yoon
Yu Jin Kim
Ka Eun Lee
Myung Jin Jung
Eun Hee Baek
Yong Soo Kim
Yea Mi Song
Jin Sung Kim
Hee Jeong Lim
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2021003204A publication Critical patent/MX2021003204A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles

Abstract

Se describe en la presente invención un compuesto de oxadiazol y sales farmacéuticamente útiles del mismo. El compuesto y sales farmacéuticamente útiles del mismo son especialmente adecuadas para el tratamiento de enfermedades del sistema nervioso tal como epilepsia.
MX2021003204A 2018-09-21 2019-09-20 Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo. MX2021003204A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180113956 2018-09-21
PCT/KR2019/012257 WO2020060299A1 (ko) 2018-09-21 2019-09-20 옥사다이아졸을 포함하는 화합물 및 이를 포함하는 약제학적 조성물

Publications (1)

Publication Number Publication Date
MX2021003204A true MX2021003204A (es) 2021-05-27

Family

ID=69887571

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003204A MX2021003204A (es) 2018-09-21 2019-09-20 Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo.

Country Status (15)

Country Link
US (3) US11053208B2 (es)
EP (1) EP3854788A4 (es)
JP (1) JP7430175B2 (es)
KR (1) KR20210047889A (es)
CN (1) CN113272285A (es)
AR (1) AR118413A1 (es)
AU (1) AU2019341357B2 (es)
BR (1) BR112021005269A2 (es)
CA (1) CA3112700A1 (es)
CL (1) CL2021000618A1 (es)
IL (1) IL281553A (es)
MX (1) MX2021003204A (es)
TW (1) TWI826531B (es)
WO (1) WO2020060299A1 (es)
ZA (1) ZA202101520B (es)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21121A (en) 1858-08-10 Appabattjs for purifying gas
DK153787C (da) 1979-06-01 1989-01-16 Wellcome Found Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
KR0162036B1 (ko) 1996-05-31 1998-12-01 추호석 스택커 크래인의 모터 제어장치 및 방법
AU740813B2 (en) * 1998-07-08 2001-11-15 Monash University Pharmaceutical agents
UA78211C2 (en) 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
EP1797094A4 (en) * 2004-08-03 2009-06-03 Merck & Co Inc 1,3-DISUBSTITUTED HETEROARYL-NMDA / NR2B ANTAGONISTS
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
CA2658887C (en) * 2006-07-28 2016-08-23 University Of Connecticut Fatty acid amide hydrolase inhibitors
MX2010008637A (es) 2008-02-06 2010-08-30 Daiichi Sankyo Co Ltd Derivado de fenilpirrol novedoso.
TWI523851B (zh) 2009-12-28 2016-03-01 Yakult Honsha Kk 1,3,4-oxadiazole-2-carboxamide
CN104710385B (zh) * 2010-03-12 2018-11-09 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
WO2017060488A1 (en) * 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists

Also Published As

Publication number Publication date
US11053208B2 (en) 2021-07-06
CN113272285A (zh) 2021-08-17
BR112021005269A2 (pt) 2021-06-15
US11603358B2 (en) 2023-03-14
EP3854788A4 (en) 2022-06-15
AU2019341357A1 (en) 2021-04-08
JP7430175B2 (ja) 2024-02-09
AR118413A1 (es) 2021-10-06
CL2021000618A1 (es) 2021-08-06
ZA202101520B (en) 2022-08-31
WO2020060299A1 (ko) 2020-03-26
TWI826531B (zh) 2023-12-21
CA3112700A1 (en) 2020-03-26
KR20210047889A (ko) 2021-04-30
EP3854788A1 (en) 2021-07-28
JP2022503775A (ja) 2022-01-12
TW202023547A (zh) 2020-07-01
US20210115001A1 (en) 2021-04-22
US20220024886A1 (en) 2022-01-27
US20230150955A1 (en) 2023-05-18
IL281553A (en) 2021-05-31
AU2019341357B2 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
PH12021500014A1 (en) Fused ring compounds
NZ765590A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
MX2023002507A (es) Inhibidores de cd73.
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MY176401A (en) Novel disubstituted 1,2,4-triazine compound
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
NZ788133A (en) Cd73 inhibitors
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
AU2024202522A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
EP4252856A3 (en) Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
TN2021000092A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
MX2019004200A (es) Terapia de combinacion.